scholarly journals Influence of Gag-Protease-Mediated Replication Capacity on Disease Progression in Individuals Recently Infected with HIV-1 Subtype C

2011 ◽  
Vol 85 (8) ◽  
pp. 3996-4006 ◽  
Author(s):  
J. K. Wright ◽  
V. Novitsky ◽  
M. A. Brockman ◽  
Z. L. Brumme ◽  
C. J. Brumme ◽  
...  
2017 ◽  
Vol 91 (13) ◽  
Author(s):  
Marion W. Kiguoya ◽  
Jaclyn K. Mann ◽  
Denis Chopera ◽  
Kamini Gounder ◽  
Guinevere Q. Lee ◽  
...  

ABSTRACT There are marked differences in the spread and prevalence of HIV-1 subtypes worldwide, and differences in clinical progression have been reported. However, the biological reasons underlying these differences are unknown. Gag-protease is essential for HIV-1 replication, and Gag-protease-driven replication capacity has previously been correlated with disease progression. We show that Gag-protease replication capacity correlates significantly with that of whole isolates (r = 0.51; P = 0.04), indicating that Gag-protease is a significant contributor to viral replication capacity. Furthermore, we investigated subtype-specific differences in Gag-protease-driven replication capacity using large well-characterized cohorts in Africa and the Americas. Patient-derived Gag-protease sequences were inserted into an HIV-1 NL4-3 backbone, and the replication capacities of the resulting recombinant viruses were measured in an HIV-1-inducible reporter T cell line by flow cytometry. Recombinant viruses expressing subtype C Gag-proteases exhibited substantially lower replication capacities than those expressing subtype B Gag-proteases (P < 0.0001); this observation remained consistent when representative Gag-protease sequences were engineered into an HIV-1 subtype C backbone. We identified Gag residues 483 and 484, located within the Alix-binding motif involved in virus budding, as major contributors to subtype-specific replicative differences. In East African cohorts, we observed a hierarchy of Gag-protease-driven replication capacities, i.e., subtypes A/C < D < intersubtype recombinants (P < 0.0029), which is consistent with reported intersubtype differences in disease progression. We thus hypothesize that the lower Gag-protease-driven replication capacity of subtypes A and C slows disease progression in individuals infected with these subtypes, which in turn leads to greater opportunity for transmission and thus increased prevalence of these subtypes. IMPORTANCE HIV-1 subtypes are unevenly distributed globally, and there are reported differences in their rates of disease progression and epidemic spread. The biological determinants underlying these differences have not been fully elucidated. Here, we show that HIV-1 Gag-protease-driven replication capacity correlates with the replication capacity of whole virus isolates. We further show that subtype B displays a significantly higher Gag-protease-mediated replication capacity than does subtype C, and we identify a major genetic determinant of these differences. Moreover, in two independent East African cohorts we demonstrate a reproducible hierarchy of Gag-protease-driven replicative capacity, whereby recombinants exhibit the greatest replication, followed by subtype D, followed by subtypes A and C. Our data identify Gag-protease as a major determinant of subtype differences in disease progression among HIV-1 subtypes; furthermore, we propose that the poorer viral replicative capacity of subtypes A and C may paradoxically contribute to their more efficient spread in sub-Saharan Africa.


2019 ◽  
Vol 24 (5) ◽  
pp. 333-342
Author(s):  
Jake Zondagh ◽  
Adriaan E Basson ◽  
Ikechukwu Achilonu ◽  
Lynn Morris ◽  
Heini W Dirr ◽  
...  

PLoS ONE ◽  
2016 ◽  
Vol 11 (9) ◽  
pp. e0161596
Author(s):  
Eveline Santos da Silva ◽  
Martin Mulinge ◽  
Morgane Lemaire ◽  
Cécile Masquelier ◽  
Cyprien Beraud ◽  
...  

2010 ◽  
Vol 84 (20) ◽  
pp. 10820-10831 ◽  
Author(s):  
Jaclyn K. Wright ◽  
Zabrina L. Brumme ◽  
Jonathan M. Carlson ◽  
David Heckerman ◽  
Carl M. Kadie ◽  
...  

ABSTRACT The mechanisms underlying HIV-1 control by protective HLA class I alleles are not fully understood and could involve selection of escape mutations in functionally important Gag epitopes resulting in fitness costs. This study was undertaken to investigate, at the population level, the impact of HLA-mediated immune pressure in Gag on viral fitness and its influence on HIV-1 pathogenesis. Replication capacities of 406 recombinant viruses encoding plasma-derived Gag-protease from patients chronically infected with HIV-1 subtype C were assayed in an HIV-1-inducible green fluorescent protein reporter cell line. Viral replication capacities varied significantly with respect to the specific HLA-B alleles expressed by the patient, and protective HLA-B alleles, most notably HLA-B*81, were associated with lower replication capacities. HLA-associated mutations at low-entropy sites, especially the HLA-B*81-associated 186S mutation in the TL9 epitope, were associated with lower replication capacities. Most mutations linked to alterations in replication capacity in the conserved p24 region decreased replication capacity, while most in the highly variable p17 region increased replication capacity. Replication capacity also correlated positively with baseline viral load and negatively with baseline CD4 count but did not correlate with the subsequent rate of CD4 decline. In conclusion, there is evidence that protective HLA alleles, in particular HLA-B*81, significantly influence Gag-protease function by driving sequence changes in Gag and that conserved regions of Gag should be included in a vaccine aiming to drive HIV-1 toward a less fit state. However, the long-term clinical benefit of immune-driven fitness costs is uncertain given the lack of correlation with longitudinal markers of disease progression.


2013 ◽  
Vol 1 (1) ◽  
pp. 4
Author(s):  
Kerina Duri ◽  
Felicity Zvanyadza Gumbo ◽  
Knut Ivan Kristiansen ◽  
Munyaradzi Paul Mapingure ◽  
Simba Rusakaniko ◽  
...  

2014 ◽  
Vol 59 (9) ◽  
pp. 1322-1331 ◽  
Author(s):  
Koleka Mlisana ◽  
Lise Werner ◽  
Nigel J. Garrett ◽  
Lyle R. McKinnon ◽  
Francois van Loggerenberg ◽  
...  

2019 ◽  
Vol 476 (2) ◽  
pp. 375-384 ◽  
Author(s):  
Alison Williams ◽  
Adriaan Basson ◽  
Ikechukwu Achilonu ◽  
Heini W. Dirr ◽  
Lynn Morris ◽  
...  

AbstractHIV protease is essential for processing the Gag polyprotein to produce infectious virions and is a major target in antiretroviral therapy. We have identified an unusual HIV-1 subtype C variant that contains insertions of leucine and asparagine (L38↑N↑L) in the hinge region of protease at position 38. This was isolated from a protease inhibitor naïve infant. Isothermal titration calorimetry showed that 10% less of L38↑N↑L protease was in the active conformation as compared with a reference strain. L38↑N↑L protease displayed a ±50% reduction in KM and kcat. The catalytic efficiency (kcat/KM) of L38↑N↑L protease was not significantly different from that of wild type although there was a 42% reduction in specific activity for the variant. An in vitro phenotypic assay showed the L38↑N↑L protease to be susceptible to lopinavir (LPV), atazanavir (ATV) and darunavir in the context of an unrelated Gag. However, in the presence of the related Gag, L38↑N↑L showed reduced susceptibility to darunavir while remaining susceptible to LPV and ATV. Furthermore, a reduction in viral replication capacity (RC) was observed in combination with the related Gag. The reduced susceptibility to darunavir and decrease in RC may be due to PTAPP duplication in the related Gag. The present study shows the importance of considering the Gag region when looking at drug susceptibility of HIV-1 protease variants.


2010 ◽  
Vol 54 (7) ◽  
pp. 2878-2885 ◽  
Author(s):  
Irene Lisovsky ◽  
Susan M. Schader ◽  
Jorge-Luis Martinez-Cajas ◽  
Maureen Oliveira ◽  
Daniela Moisi ◽  
...  

ABSTRACT The amino acid at position 36 of the HIV-1 protease differs among various viral subtypes, in that methionine is usually found in subtype B viruses but isoleucine is common in other subtypes. This polymorphism is associated with higher rates of treatment failure involving protease inhibitors (PIs) in non-subtype B-infected patients. To investigate this, we generated genetically homogeneous wild-type viruses from subtype B, subtype C, and CRF02_AG full-length molecular clones and showed that subtype C and CRF02_AG I36 viruses exhibited higher levels of resistance to various PIs than their respective M36 counterparts, while the opposite was observed for subtype B viruses. Selections for resistance with each variant were performed with nelfinavir (NFV), lopinavir (LPV), and atazanavir (ATV). Sequence analysis of the protease gene at week 35 revealed that the major NFV resistance mutation D30N emerged in NFV-selected subtype B viruses and in I36 subtype C viruses, despite polymorphic variation. A unique mutational pattern developed in subtype C M36 viruses selected with NFV or ATV. The presence of I47A in LPV-selected I36 CRF02_AG virus conferred higher-level resistance than L76V in LPV-selected M36 CRF02_AG virus. Phenotypic analysis revealed a >1,000-fold increase in NFV resistance in I36 subtype C NFV-selected virus with no apparent impact on viral replication capacity. Thus, the position 36 polymorphism in the HIV-1 protease appears to have a differential effect on both drug susceptibility and the viral replication capacity, depending on both the viral subtype and the drug being evaluated.


AIDS ◽  
2013 ◽  
Vol 27 (4) ◽  
pp. 507-518 ◽  
Author(s):  
Melissa-Rose Abrahams ◽  
Florette K. Treurnicht ◽  
Nobubelo K. Ngandu ◽  
Sarah A. Goodier ◽  
Jinny C. Marais ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document